Sequential versus concomitant treatment of androgen receptor signaling inhibitors and docetaxel for metastatic hormone-sensitive prostate cancer: an network meta-analysis.

Front Pharmacol · 2024 · PMC11551020 · PMID 39529878

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

The results revealed that compared to docetaxel, enzalutamide sequential therapy (HR: 0.22, 95% CI: 0.03–1.67) and enzalutamide combined therapy (HR: 0.46, 95% CI: 0.06–3.07) exhibited a favorable trend in enhancing the time to PSA progression in mHSPC patients ( Supplementary Material 6R ).

also in 714 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.